Longterm outcome of TNF blockade in adult-onset Still's disease;Langzeitergebnisse einer TNF-blockade beim morbus Still im erwachsenenalter

Deutsche Medizinische Wochenschrift

Volumn 129, Issue 23, 2004, Pages 1308-1312

  Dechant, C ^a,b   Schauenberg, P ^a   Antoni, C E ^a   Kraetsch, H C ^a   Kalden, J R ^a   Manger, B ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ADULT ONSET STILL DISEASE; ARTHRALGIA; CHRONIC ARTHRITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; FEVER; FOLLOW UP; HEALTH SURVEY; HEPATOSPLENOMEGALY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PREMEDICATION; REMISSION; REVIEW; SEROLOGY; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; STILL'S DISEASE, ADULT-ONSET; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3042620309     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-826865     Document Type: Review

References (14)

1. Aeberli D, Oertle S, Mauron H et al. Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly 2002; 132: 414-422
2. Asherson RA, Pascoe L. Adult onset Still's disease: response to Enbrel. Ann Rheum Dis 2002; 61: 859-60; author reply 860.
3. Caramaschi P, Biasi D, Carletto A, Bambara LM. A case of adult onset Still's disease treated with infliximab. Clin Exp Rheumatol 2002; 20: 113
4. Cavagna L, Caporali R, Epis O, Bobbio-Pallavicini F, Montecucco C. Infliximab in the treatment of adult Still's disease refractory to conventional therapy. Clin Exp Rheumatol 2001; 19: 329-32
5. Domm A. A patient's reaction to infliximab. Ann Allergy Asthma Immunol 2003; 90: 298-301
6. Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-735
7. Hoshino T, Ohta A, Yang D et al. Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still's disease. J Rheumatol 1998; 25: 396-398
8. Husni ME, Maier AL, Mease PJ et al. Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum 2002; 46: 1171-1176
9. Kraetsch HG, Antoni C, Kalden JR, Manger B. Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences. Ann Rheum Dis 2001; 60: iii55-57
10. Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol 2003; 30: 1624-1625
11. Olivieri I, de Stefano G, Padula A, La Gala A, de Stefano C. Infliximab in a case of early adult-onset Still's disease. Clin Rheumatol 2003; 22: 369-370
12. Serratrice J, Granel B, Disdier P, Weiller PJ, Dussol B. Resolution with etanercept of nephrotic syndrome due to renal AA amyloidosis in adult Still's disease. Am J Med 2003; 115: 589-590
13. Stambe C, Wicks IP. TNFalpha and response of treatment-resistant adult-onset Still's disease to thalidomide. Lancet 1998; 352: 544-545
14. Yamaguchi M, Ohta A, Tsunematsu T et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992; 19: 424-430